Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma

Inclusion Criteria: * Patients who have been diagnosed, by cytologic or histologic examination, with AJCC stage IIB, stage III or resected stage IV melanoma. * Patients with up to 2 brain metastases less than or equal to 2 cm that have been surgically removed or treated successfully with the gamma-knife are eligible. Surgical resections must have been performed within 6 months prior to entry. * All patients must have: 1. ECOG performance status 0-1, and, 2. Ability and willingness to give informed consent. * Laboratory parameters as follows: * HLA-A1, A2 or A3 (+) * gp100 (+) and/or tyrosinase (+) tumor cells * ANC \> 1000/mm3, and Platelets \> 100,000 and Hgb \> 9 * Hepatic: AST and ALT up to 2.5 x upper limits of normal (ULN), Bilirubin up to 2.5 x ULN, Alkaline phosphatase up to 2.5 x ULN * Renal: Creatinine up to 1.5 x ULN * Serology: HIV negative, Hepatitis C negative Exclusion criteria: * Patients who are currently receiving cytotoxic Chemotherapy or radiation or who have received that therapy within the preceding 4 weeks. * Patients with known or suspected allergies to any component of the vaccine. * Patients receiving the following medications at study entry or within the preceding 30 days are excluded: * Agents with putative immunomodulating activity (with the exception of non-steroidal anti-inflammatory agents) * Allergy desensitization injections * Corticosteroids, administered parenterally or orally - topical corticosteroids are acceptable * Any growth factors, Interleukin 2, Interferon alfa. * Prior melanoma vaccinations will not be an exclusion criteria if given more than 8 weeks previously, but will be recorded, and data analysis will take this into account. * Other investigational drugs or investigational therapy also will not necessarily be an exclusion criteria, but will similarly be recorded and taken into account during data analysis. * Pregnancy or the possibility of becoming pregnant during vaccine administration. * Female patients of child-bearing potential must have a negative pregnancy test (urinary or serum beta-HCG) prior to administration of the first vaccine dose. * Males and females must agree, in the consent form, to use effective birth control methods during the course of vaccination. * This is consistent with existing standards of practice for vaccine and chemotherapy protocols. * Patients in whom there is a medical contraindication or potential problem in complying with the requirements of the protocol, in the opinion of the investigator. * Patients classified according to the New York Heart Association classification system as having Class II, III or IV heart disease. * Patients with active connective tissue disease requiring medication, or other severe autoimmune disease. * Patients who are actively hyperthyroid. * Patients with uncontrolled diabetes.